Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Schistosoma mansoni | pyruvate dehydrogenase | 0.2761 | 0.3067 | 0.0778 |
Brugia malayi | kinase, mitochondrial precursor | 0.2761 | 0.3067 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.4583 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.2705 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.4506 | 0.9706 | 0.9604 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.4506 | 0.9706 | 0.9706 |
Trypanosoma cruzi | developmentally regulated phosphoprotein, putative | 0.2761 | 0.3067 | 0.3067 |
Giardia lamblia | Hypothetical protein | 0.2705 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.4506 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Schistosoma mansoni | 6-phosphofructokinase | 0.4583 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.2705 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.2705 | 0.2852 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.4583 | 1 | 1 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.2705 | 0.2852 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4506 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.4583 | 1 | 1 |
Trypanosoma brucei | developmentally regulated phosphoprotein | 0.2761 | 0.3067 | 0.3067 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.4506 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2761 | 0.3067 | 0.0685 |
Onchocerca volvulus | 0.4583 | 1 | 0.5 | |
Leishmania major | developmentally regulated phosphoprotein-like protein | 0.2761 | 0.3067 | 0.3067 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.